Poland vs Russian Federation: Prevalence rate of diabetes in adults
Poland
7.7
in 2014
Russian Federation
7.7
in 2014
Poland rank
106th
Russian Federation rank
106th
Prevalence rate of diabetes in adults over time
- Poland
- Russian Federation
How they compare
Poland currently reports 7.7 against 7.7 in Russian Federation, a difference of 0.
Across all 35 years both countries report, Russian Federation has been ahead every year.
Poland ranks 106th and Russian Federation ranks 106th of 190 countries.
Russian Federation has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Poland | Russian Federation | Difference | Ahead |
|---|---|---|---|---|
| 1980s | 5.87 | 6.72 | 0.85 | Russian Federation |
| 1990s | 6.19 | 6.81 | 0.62 | Russian Federation |
| 2000s | 6.72 | 7.16 | 0.44 | Russian Federation |
| 2010s | 7.42 | 7.6 | 0.18 | Russian Federation |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of diabetes in adults, Poland or Russian Federation?
- Poland, at 7.7 against 7.7 in Russian Federation as of 2014.
- What is the difference in prevalence rate of diabetes in adults between Poland and Russian Federation?
- 0, with Poland ahead.
- How many years of comparable data are there for Poland and Russian Federation?
- 35 years are reported by both, from 1980 to 2014.
- How do Poland and Russian Federation rank globally for prevalence rate of diabetes in adults?
- Poland ranks 106th and Russian Federation ranks 106th of 190 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) β with minor processing by Our World in Data, published as Prevalence rate of diabetes in adults. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of people with diabetes among those aged over 18, based on general population surveys and statistical modeling. Diabetes is a risk factor for chronic complications, including cardiovascular disease, and premature death.